Vir Biotechnology, Inc. — Director's Dealing 2021

Apr 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vir Biotechnology, Inc. (VIR)
CIK: 0001706431
Period of Report: 2021-04-01

Reporting Person: Parrish Jay (Chief Business Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-01	Common Stock	M	4629	$1.485	Acquired	13889	Direct
2021-04-01	Common Stock	M	2315	$1.575	Acquired	16204	Direct
2021-04-01	Common Stock	S	6944	$51.4049	Disposed	9260	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-01	Stock Option (Right to Buy)	$1.485	M	4629	Disposed	2027-10-05	Common Stock (4629)	Direct
2021-04-01	Stock Option (Right to Buy)	$1.575	M	2315	Disposed	2028-07-19	Common Stock (2315)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020.

F2: 1/4 of the shares subject to the stock option vested and became exercisable on April 3, 2018, and the remaining shares vest in 36 equal monthly installments thereafter.

F3: 1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.